<DOC>
	<DOCNO>NCT00741156</DOCNO>
	<brief_summary>The primary objective study study acute effect angiotensin-converting enzyme inhibitor ( ACEI ) systemic , pulmonary cerebral blood flow post bidirectional cavopulmonary connection ( BCPC ) patient .</brief_summary>
	<brief_title>The Acute Effects Angiotensin-converting Enzyme Inhibitor Enalaprilat Flow Distribution</brief_title>
	<detailed_description>The intermediate stage bi-directional cavopulmonary connection ( BCPC ) management algorithm single ventricle palliation unique extraordinary physiologic condition . It place superior vena caval blood flow series lung i.e . pulmonary blood flow partially dependent cerebral vascular flow resistance . Differential reduction resistance systemic , cerebral pulmonary vascular bed result re-equilibrium relative blood flow translate alteration arterial oxygen tension perfusion pressure . This concept demonstrate differential effect carbon dioxide ( CO2 ) oxygen ( O2 ) . CO2 vasodilates oxygen ( O2 ) vasoconstricts cerebral vascular bed ; opposite true lung . Furthermore , study demonstrate arterial CO2 tension ( PaCO2 ) hypercarbic level favourable normocarbia increase pulmonary , systemic cerebral blood flow reduce systemic vascular resistance acute post BCPC patient . Administration angiotensin-converting enzyme inhibitor ( ACEI ) systemic vasodilator drug well establish treatment patient hypertension congestive cardiomyopathy pediatric adult population . Favourable manipulation flow different vascular bed report child significant intra-cardiac shunt pulmonary blood flow decrease relative increase systemic blood flow result reduction systemic vascular resistance . Guided similar principle , ACEI therapy administer patient single ventricle physiology redistribute relative blood flow across pulmonary systemic vascular bed . To date , exist study examine hemodynamic effect ACEI relative blood flow set single ventricle physiology particular , study demonstrate benefit . The effect ACEI unknown equilibrium relative cerebral , systemic pulmonary blood flow post-BCPC state . A relative increase systemic blood flow , effect ACEI , expense cerebral blood flow may potentially adversely decrease pulmonary blood ultimately reduce arterial oxygen tension . On hand , data suggest ACEI 's improve cerebral autoregulation function ; drop blood pressure signal vasodilatory response cerebral vascular bed may particularly advantageous BCPC patient . Enalaprilat active diacid ACEI enalapril maleate . Doses 0.01 0.06 mg/kg i.v . safely administer pediatric study . Onset action 15 minute duration action 12-24 hour . The pharmacokinetics drug ideal purpose study . In institution , patient undergo routine cardiac catheterization BCPC procedure hemodynamic assessment angiography cardiac structure assess eligibility Fontan operation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>BCPC patient time routine preFontan catheterization Patients age 2 month 5 year old Patients ACEI therapy within 24 hour procedure</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>pediatric</keyword>
	<keyword>hypertension</keyword>
	<keyword>congestive cardiomyopathy</keyword>
	<keyword>angiotensin-converting enzyme inhibitor</keyword>
	<keyword>cardiac catheterization</keyword>
</DOC>